Table 3 Summary of adverse events related to treatment with at least 10% incidence—by cohort
From: Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases
| Overall | Cohort | |||||||
|---|---|---|---|---|---|---|---|---|
| HER2-negative (N = 9) | HER2-positive (N = 29) | |||||||
| Grade | Grade | |||||||
| N | 1 | 2 | 3 | 1 | 2 | 3 | 4 | |
| AE name | ||||||||
| Hemoglobin | 29 (76%) | 4 (44%) | 3(33%) | 10 (34%) | 11 (38%) | 1 (3%) | ||
| Fatigue | 28 (74%) | 1 (11%) | 3(33%) | 2(22%) | 9 (31%) | 9 (31%) | 4 (14%) | |
| Platelets | 28 (74%) | 3 (33%) | 3(33%) | 6 (21%) | 12 (41%) | 3 (10%) | 1 (3%) | |
| AST | 23 (61%) | 5 (56%) | 1(11%) | 15 (52%) | 2 (7%) | |||
| 22 (58%) | 2 (22%) | 1(11%) | 3 (10%) | 13 (45%) | 3 (10%) | |||
| Head/headache | 20 (53%) | 4 (44%) | 10 (34%) | 6 (21%) | ||||
| Hyperglycemia | 18 (47%) | 3 (33%) | 1(11%) | 12 (41%) | 2 (7%) | |||
| Leukocytes | 18 (47%) | 4 (14%) | 14 | |||||
| Nausea | 17 (45%) | 1 (11%) | 1(11%) | 13 (45%) | 2 (7%) | |||
| ALT | 14 (37%) | 3 (33%) | 1(11%) | 8 (28%) | 2 (7%) | |||
| Constipation | 14 (37%) | 3(33%) | 1(11%) | 7 (24%) | 3 (10%) | |||
| Neuropathy-sensory | 14 (37%) | 3(33%) | 9 (31%) | 2 (7%) | ||||
| Nose, hemorrhage | 12 (32%) | 1(11%) | 9 (31%) | 2 (7%) | ||||
| Alkaline phosphatase | 11 (29%) | 9 (31%) | 2 (7%) | |||||
| Diarrhea w/o prior colostomy | 11 (29%) | 1(11%) | 1(11%) | 7 (24%) | 2 (7%) | |||
| Cough | 9 (24%) | 8 (28%) | 1 (3%) | |||||
| Hypertension | 9 (24%) | 6 (21%) | 2 (7%) | 1 (3%) | ||||
| Alteration in bone age | 8 (21%) | 6 (21%) | 2 (7%) | |||||
| Proteinuria | 8 (21%) | 1(11%) | 6 (21%) | 1 (3%) | ||||
| Extremity-limb, pain | 7 (18%) | 4 (14%) | 2 (7%) | 1 (3%) | ||||
| Alopecia | 6 (16%) | 1(11%) | 4 (14%) | 1 (3%) | ||||
| Hyponatremia | 6 (16%) | 5 (17%) | 1 (3%) | |||||
| Joint, pain | 6 (16%) | 3 (10%) | 2 (7%) | 1 (3%) | ||||
| Vomiting | 6 (16%) | 2(22%) | 1(11%) | 2 (7%) | 1 (3%) | |||
| Allergic reaction | 5 (13%) | 1 (3%) | 4 (14%) | |||||
| Back, pain | 5 (13%) | 4 (14%) | 1 (3%) | |||||
| Dizziness | 5 (13%) | 2 (7%) | 3 (10%) | |||||
| Infection Grade 0–2, upper airway | 5 (13%) | 4 (14%) | 1 (3%) | |||||
| Left ventricular systolic dysfunction | 5 (13%) | 5 (17%) | ||||||
| Pain-other | 5 (13%) | 1(11%) | 1(11%) | 1 (3%) | 2 (7%) | |||
| Rectum, hemorrhage | 5 (13%) | 4 (14%) | 1 (3%) | |||||
| Bone, pain | 4 (11%) | 4 (14%) | ||||||
| CNS, hemorrhage | 4 (11%) | 1(11%) | 1(11%) | 2 (7%) | ||||
| Constitutional, other | 4 (11%) | 3 (10%) | 1 (3%) | |||||
| Creatinine | 4 (11%) | 2(22%) | 2 (7%) | |||||
| GI-other | 4 (11%) | 4 (14%) | ||||||
| Hypocalcemia | 4 (11%) | 4 (14%) | ||||||
| Hypokalemia | 4 (11%) | 1(11%) | 3 (10%) | |||||
| Metabolic/laboratory-other | 4 (11%) | 2(22%) | 1(11%) | 1 (3%) | ||||
| Skin-other | 4 (11%) | 2(22%) | 1 (3%) | 1 (3%) | ||||
| Throat/pharynx/larynx, pain | 4 (11%) | 4 (14%) | ||||||
